variety promising targeted radiotherapeutics labeled developed clinical investigation radiopharmaceuticals requires production high activity levels hindered radiolytic effects labeling chemistry purpose study investigate effects radiation dose synthesis 3211atastatobenzoate sab compound used clinical trials labeling antibodies 211at methods yields synthesis sab function radiation dose received reaction medium determined variables studied included radiohalogenation precursors 3trinbutylstannylbenzoate bustb 3trimethylstannylbenzoate mestb solvents chloroform benzene methanol addition acetic acid oxidant 211at product spectra determined liquid chromatograms plotted radiation dose results sab production declined rapidly increasing dose consistent documented radiolytic decomposition bustb mestb chloroform tin precursors appreciably degraded benzene sab produced solvent instead highly lipophilic species generated nearly quantitative yields decline sab yield observed methanol presence absence oxidant results better obtained solvents unexpected observation sab obtained yield greater NUMBER reaction run methanol addition acetic acid oxidant NUMBER components previously considered essential astatodestannylation conclusion radiolytic factors play important role synthesis activities radiopharmaceuticals necessitating development reaction conditions different used successfully lower activity levels alpha emitters alpha particle mediated n succinimidyl alpha particle emitting n succinimidyl n succinimidyl n chlorosuccinimide high performance 211at labeled dose dependent clinical level 211at labeled